Preventing shivering with adjuvant low dose intrathecal meperidine: A meta-analysis of randomized controlled trials with trial sequential analysis.

Yu-Cih Lin, RNA^{1,2}; Chien-Yu Chen, MD, PhD^{1,3,4}; Yuan-Mei Liao, RN, PhD^{2,5}; Alan Hsi-Wen Liao, MBchB¹; Pi-Chu Lin, RN, EdD^{2,6}; Chuen-Chau Chang, MD, PhD^{1,2,3,*}
¹Department of Anaesthesiology, Taipei Medical University Hospital, Taipei, 110, Taiwan
²School of Nursing, College of Nursing, Taipei Medical University, Taipei, 110, Taiwan
³Department of Anaesthesiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 110, Taiwan
⁴Graduate Institute of Humanities in Medicine, Taipei Medical University, Taipei, 110, Taiwan
⁵Institute of Clinical Nursing, School of Nursing, National Yang-Ming University, Taipei City, 112, Taiwan
⁶Master Program in Long-Term Care, College of Nursing, Taipei Medical University, Taipei, 110, Taiwan

Corresponding author: Chuen-Chau Chang, Taipei Medical University Hospital 252 Wuxing St., Taipei 11031, Taiwan Tel.: 886-2-2737-2181, ext. 8310 Fax: 886-2-2736-7344 E-mail: nekota@tmu.edu.tw (Chuen-Chau Chang)

Short title: Preventing shivering with adjuvant intrathecal meperidine Word count for abstract: 208 Word count for text: 3815 (including Methods)

Supplementary Table 1. Risk of bias of selection randomized controlled trials.

Study (year)	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Anaraki and Mirzaei (2012) ²⁵	L	U	L	L	L	L	L
Anaraki, <i>et al</i> . (2012) ^{<u>47</u>}	L	L	L	L	L	L	Ha
Chen, et al. (1993) ⁴⁹	U	U	L	U	L	L	H ^b
Choi, <i>et al</i> . (2000) ⁵³	U	U	L	U	L	L	L
Chun, <i>et al</i> . (2010) ^{<u>44</u>}	L	U	L	U	L	L	L
Chung, et al. (1997) ⁵²	L	L	L	U	L	L	L
Davoudi, <i>et al.</i> (2007) ⁵⁵	L	U	L	U	L	L	L
Farzi, <i>et al</i> . (2014) <u>58</u>	U	U	L	L	L	L	L
Fidan, <i>et al.</i> (2008) ⁴⁵	U	U	L	L	Н	L	L
Fu and Chang (2008) ⁴³	L	U	L	U	L	L	H ^{d, g}
Han, <i>et al</i> . (2007) ⁵⁶	U	U	L	L	L	L	L
Honarmand, <i>et al.</i> (2015) ^{<u>26</u>}	L	L	L	L	L	L	H¢
Hong and Lee (2005) ²⁸	L	L	L	L	Н	L	H ^{d, g}
Imarengiaye, <i>et al.</i> (2011) ³¹	L	L	L	L	L	L	He
Khan, <i>et al</i> . (2011) ²⁷	L	U	L	L	L	L	L
Köroğlu, <i>et al</i> . (2003) ⁵⁰	U	U	U	U U L		L	L
Murto, <i>et al</i> . (1999) ¹⁶	L	U	L	L	L	L	L
Nag and Gode (1984) <u>54</u>	U	U	U	U	L	L	L
Rastegarian, <i>et al.</i> (2013) ²⁹	Н	L	L	L	L	L	L
Roy, <i>et al</i> . (2004) ^{<u>57</u>}	L	L	L	L	L	L	L
Safavi, <i>et al</i> . (2014) ³⁰	L	L	U	L	L	L	L
Safavi, <i>et al</i> . (2014) ^{<u>46</u>}	L	U	L	L	L	L	Uf
Shami, <i>et al</i> . (2016) ⁵⁹	L	L	L	U	L	L	Ha
Tzeng, et al. (1987) ³³	U	U	U	U	L	L	L
Wang, et al. (2013) ⁴²	L	U	L	U	L	L	U ^{d, g}
Yi, et al. (2005) ⁵¹	U	U	U	U	L	L	L
Yu, et al. (2002) ³²	L	L	L	U	L	L	L
Zabetian, et al. (2013)48	L	L	L	L	L	L	L

H, high risk; L, low risk; U, unclear risk; ^a Data error noted in manuscript; ^b Different shivering assessment scale;

^c Data errors noted on table 1; ^d Spinal and epidural anaesthesia combined; ^e Only post-operation shivering assessed;

^f No indication of what kind of shivering assessment scale adopted; ^g Spinal needle size unclear

Out and the	Group I		Group II		Relative risk		lative risk	Relative risk	
Subgroup	Events	Total	Events	Total	Weight	M-H,Ra	andom,95%Cl	M-H,Random,95%CI	
1.Incidence of shivering									
Anaraki and Mirzaei (2012) ²⁵	15	39	17	78	41.5%	1.76	[0.99, 3.15]		
Honarmand, <i>et al.</i> (2015) ²⁶	26	60	3	30	27.4%	4.33	[1.43, 13.17]		
Khan, <i>et al.</i> (2011) ²⁷	2	24	5	24	19.2%	0.40	[0.09, 1.86]		
Wang, <i>et al.</i> (2013) ⁴²	3	30	1	15	11.9%	1.50	[0.17, 13.23]		
Subtotal (95% Cl)		153		147	100.0%	1.66	[0.71, 3.91]	◆	
Total events	46		26						
Heterogeneity: $Tau^2 = 0.37$; C Test for overall effect: $Z = 1.1$	2017 Chi ² = 6.17 7 (<i>P</i> = 0.2	′, df = 3 24)	(<i>P</i> = 0.10);	<i>l</i> ² = 51%	0				
2. Incidence of need for ana	algesics								
Anaraki and Mirzaei (2012) ²⁵	2	39	4	78	43.7%	1.00	[0.19, 5.22]	_	
Murto, <i>et al.</i> (1999) ¹⁶	5	14	2	13	56.3%	2.32	[0.54, 9.95]		
Subtotal (95% CI)		53		91	100.0%	1.61	[0.54, 4.79]		
Total events	7		6	0.	10010 /0		[0:04, 4:10]		
Heterogeneity: $Tau^2 = 0.00^{\circ}$	، hi² = 0 56:	df = 1	(P = 0.45)	<i>l</i> 2= 0%					
Test for overall effect: $Z = 0.8$	5 (P = 0.3)	39)	(1 0.40),	1 070					
3. Incidence of nausea	- (* ***	- /							
Khan <i>et al.</i> $(2011)^{27}$	18	24	5	24	38.4%	3 60	[1 60 8 12]		
Murto, <i>et al.</i> $(1999)^{16}$	2	13	1	14	24.4%	2.15	[0.22, 21.03]	_	
Wang, <i>et al.</i> $(2013)^{42}$	5	30	7	15	37.1%	0.36	[0.14, 0.94]		
Subtotal (95% CI)		67		53	100.0%	1.35	[0.24, 7.69]		
Total events	25		13				• • •		
Heterogeneity: Tau ² = 1.89; C	Chi² = 13.0)5, df = 2	2(P = 0.00)	1); <i>I</i> ² = 8	5%				
Test for overall effect: $Z = 0.3$	3 (<i>P</i> = 0.7	' 4)							
4. Incidence of vomiting	,	,							
Anaraki and Mirzaei (2012) ²⁵	6	39	24	78	54.0%	0.50	[0.22, 1.12]		
Khan, <i>et al.</i> (2011) ²⁷	11	24	1	24	46.0%	11.00	[1.54, 78.67]		
Subtotal (95% CI)		63		102	100.0%	2.08	[0.09, 49.90]		
Total events	17		25						
Heterogeneity: $Tau^2 = 4.71$; C	$hi^2 = 9.00$), $df = 1$	(P = 0.003)); /² = 89	%				
l est for overall effect: $\angle = 0.4$	-5(P=0.6)	5)							
5. Incluence of pruritus	11	20	24	70	100.0%	0.65	[0 27 4 4 2]	_	
Khap $et al. (2011)^{27}$	0	24	34 0	70 24	100.070	0.05	[0.37, 1.13]	—	
Murto et al. $(1999)^{16}$	0	13	0	14			Not estimable		
Subtotal (95% CI)	Ŭ	76	Ũ	116	100.0%	0.65	[0.37.1.13]		
Total events	11		34					•	
Heterogeneity: Not applicable)								
Test for overall effect: Z = 1.5	52 (<i>P</i> = 0.1	3)							
6.Incidence of bradycardia									
Anaraki and Mirzaei (2012) ²⁵	0	39	0	78			Not estimable		
Khan, <i>et al.</i> (2011) ²⁷	1	24	0	24	28.2%	3.00	[0.13, 70.16]		
Murto, <i>et al.</i> (1999) ¹⁶	6	13	1	14	71.8%	6.46	[0.89, 46.70]		
Subtotal (95% CI)	-	76		116	100.0%	5.20	[0.97, 27.79]		
	/		1	10 00/					
Heterogeneity: $Iau^2 = 0.00$; C	h' = 0.16	5, df = 1	(P = 0.69);	<i>I</i> ′ = 0%					
T rest for overall effect: $\angle = 1.9$	າວ (<i>P</i> = 0.0	13)							
Anaraki and Mirzaei (2012) ²⁵	•	30	Ω	78			Not estimable		
Khan $et al (2011)^{27}$	11	24	12	70 24	100%	0 92	[0 51 1 66]	.	
Subtotal (95% Cl)		63	14	102	100%	0.92	[0.51. 1.66]	\mathbf{A}	
Total events	11		12			5.04			
Heterogeneity: Not applicable	;						0.005	0.1 1 10 200	
Test for overall effect: Z = 0.2	9 (<i>P</i> = 0.7	7)					Favours	s Group I Favours Group II	

Supplementary Figure 1. Comparing dose equal to or less than 0.2 mg kg⁻¹ or 12.5 mg (Group I) and dose more than 0.2 mg kg⁻¹ or 12.5 mg (Group II) of adjuvant intrathecal meperidine in incidence of shivering and secondary outcomes.



Supplementary Figure 2. Meta-regression of shivering for covariates of age, meperidine dose, and sample size of each study.